Chandra Bhagat Pharma to raise ₹29.04 cr via warrants in 2026

Key decision: preferential warrants fundraise

Chandra Bhagat Pharma Limited has announced a plan to raise capital through a preferential issue of convertible warrants. The proposal targets ₹29.04 crore through the issuance of 66,00,000 warrants. Each warrant is priced at ₹44, which includes a premium of ₹34. The company said these decisions were taken at its board meeting held on August 5, 2026. Alongside fundraising, the board also cleared a proposal to expand the company’s authorized share capital. The announcement is an important corporate action because it can lead to equity dilution over time if the warrants are converted into shares.

What the board approved on August 5, 2026

At the August 5, 2026 meeting, the board approved the issuance of 66 lakh convertible warrants on a preferential basis. The stated fundraise size is ₹29.04 crore based on the issue price of ₹44 per warrant. The company also proposed increasing authorized share capital to ₹15 crore. The authorized capital increase is intended to accommodate future equity requirements, as per the details provided. These actions are not final until shareholders vote in favour of the resolutions.

Warrant structure: pricing, upfront payment, and conversion

The issue price has been set at ₹44 per warrant, including a premium of ₹34. Investors are required to pay 25% of the amount upfront at the time of allotment. The remaining 75% will be payable when the warrants are converted into equity shares. The company stated that the warrants can be converted into equity shares within 18 months from the date of allotment. This means any actual equity dilution is expected to happen gradually as conversion takes place over the conversion window, rather than immediately at the time of warrant issuance.

Authorized share capital to rise from ₹8.5 crore to ₹15 crore

Separately, the board approved an increase in authorized share capital from ₹8.5 crore to ₹15 crore. The company linked this to the need to meet future equity requirements. In practical terms, increasing authorized capital expands the legal limit on how much share capital the company can issue, subject to required approvals. This step is commonly paired with planned issuances such as warrants or equity allotments, because it ensures adequate headroom for conversion into shares.

Shareholder approval and AGM date

Both the preferential issue of convertible warrants and the authorized capital increase are subject to shareholder approval. The company has scheduled the Annual General Meeting (AGM) for September 1, 2026, where shareholders will vote on these proposals. Until that approval is received, the board’s decisions remain proposals. If shareholders approve the resolutions, the conversion-based dilution will then occur over the following 18 months as warrants are converted.

Trading window closure around the board meeting

The disclosures also referenced insider-trading compliance steps around the board meeting. The trading window was stated to remain closed for connected persons, officers, designated employees, directors, and their immediate relatives. The restriction applies from July 30, 2026, until 48 hours after the conclusion of the board meeting. Such trading-window closures typically accompany price-sensitive corporate actions, and the company’s timeline here is tied specifically to the August 5, 2026 board meeting.

Financial snapshot: FY26 profit and revenue growth

Chandra Bhagat Pharma reported a sharp improvement in profitability for FY26. Net profit increased 255% to ₹3.0461 crore (₹304.61 lakh). Revenue from operations rose 30.9% to ₹116.2717 crore (₹11,627.17 lakh). These figures provide context for the fundraising plan, as investors often track whether capital raising coincides with improving operating performance.

Stock and listing details available in the data

The information provided includes market and listing references for the company. Chandra Bhagat Pharma is listed on BSE with code 542934 and is not listed on NSE. One snapshot in the provided data shows the share price at ₹40 with an indicated market capitalisation of about ₹30.180224 crore. Another snapshot shows the stock last traded at ₹44 with a stated move of -13.64% from a previous close of ₹50.95. The data also includes a 52-week high of ₹61.5 and a 52-week low of ₹29.7, along with a session high of ₹41.8 and low of ₹38 in one market snapshot.

Summary table: what is confirmed so far

What investors are tracking next

The next defined event in this process is the shareholder vote at the AGM scheduled for September 1, 2026. The company has indicated that shareholder approval is a condition for both the warrant issue and the authorized capital increase. If approved, the key operational point to monitor will be the pace of warrant conversion, because that is when equity shares would be issued and dilution would occur. The company has also specified the conversion period as 18 months from allotment, setting a clear time frame for when conversion-related changes could take place.

Why the development matters

A preferential warrant issue changes the company’s future equity base if the warrants are converted. The structured payment schedule, where 25% is paid upfront and the rest on conversion, also spreads the funding inflow across the conversion timeline. The authorized share capital increase to ₹15 crore indicates preparation for additional equity issuance capacity. Separately, the FY26 financial numbers mentioned in the disclosures show revenue and profit growth, which provides additional context for why the company may be planning a capital-raising step.

Conclusion

Chandra Bhagat Pharma’s board has approved a plan to raise ₹29.04 crore through 66 lakh convertible warrants at ₹44 each and to increase authorized share capital to ₹15 crore. Both proposals will go to shareholders at the AGM on September 1, 2026. If shareholders approve, equity dilution would occur over the subsequent 18 months as and when the warrants are converted into equity shares.